Compton Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Compton Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,000	Closed	-$11K	–	143
2016 Q4	$11K	Sell	10,000 -10,000	-50%	-$11.4K	0.01%	136
2016 Q3	$18K	Buy	20,000 +10,000	+100%	+$9K	0.01%	145
2016 Q2	$7K	Buy	+10,000	New	+$8.05K	﹤0.01%	142

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Compton Capital Management's CPRX Position: Q1 2017 in Review

Compton Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2017, closing a stake of 10,000 shares — an estimated $11K sold.

Compton Capital Management first reported a position in CPRX in Q2 2016 and held it in 3 quarters. The position peaked at $18K in Q3 2016. 50 funds tracked by Wall St. Rank hold CPRX as of Q1 2017.

Compton Capital Management reported no remaining Catalyst Pharmaceutical position as of Q1 2017 after selling out during the quarter.
Compton Capital Management sold 10,000 Catalyst Pharmaceutical shares in Q1 2017, an estimated $11K.
Compton Capital Management first reported a position in Catalyst Pharmaceutical in Q2 2016 and held it in 3 quarters.
Compton Capital Management's Catalyst Pharmaceutical position peaked at $18K in Q3 2016.
50 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2017.

Based on Compton Capital Management's 13F filing for Q1 2017, filed 9 May 2017.